305 related articles for article (PubMed ID: 21789172)
21. Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.
Zhou H; Kim YS; Peletier A; McCall W; Earp HS; Sartor CI
Int J Radiat Oncol Biol Phys; 2004 Feb; 58(2):344-52. PubMed ID: 14751502
[TBL] [Abstract][Full Text] [Related]
22. EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen.
Scheipl S; Barnard M; Cottone L; Jorgensen M; Drewry DH; Zuercher WJ; Turlais F; Ye H; Leite AP; Smith JA; Leithner A; Möller P; Brüderlein S; Guppy N; Amary F; Tirabosco R; Strauss SJ; Pillay N; Flanagan AM
J Pathol; 2016 Jul; 239(3):320-34. PubMed ID: 27102572
[TBL] [Abstract][Full Text] [Related]
23. Preclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2.
Tanaka H; Hirata M; Shinonome S; Wada T; Iguchi M; Dohi K; Inoue M; Ishioka Y; Hojo K; Yamada T; Sugimoto T; Masuno K; Nezasa K; Sato N; Matsuo K; Yonezawa S; Frenkel EP; Shichijo M
Cancer Sci; 2014 Aug; 105(8):1040-8. PubMed ID: 24837299
[TBL] [Abstract][Full Text] [Related]
24. Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program.
Gorlick R; Kolb EA; Houghton PJ; Morton CL; Phelps D; Schaiquevich P; Stewart C; Keir ST; Lock R; Carol H; Reynolds CP; Maris JM; Wu J; Smith MA
Pediatr Blood Cancer; 2009 Oct; 53(4):594-8. PubMed ID: 19554571
[TBL] [Abstract][Full Text] [Related]
25. Preclinical assessment of simultaneous targeting of epidermal growth factor receptor (ErbB1) and ErbB2 as a strategy for cholangiocarcinoma therapy.
Zhang Z; Oyesanya RA; Campbell DJ; Almenara JA; Dewitt JL; Sirica AE
Hepatology; 2010 Sep; 52(3):975-86. PubMed ID: 20607690
[TBL] [Abstract][Full Text] [Related]
26. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor.
Fry DW; Bridges AJ; Denny WA; Doherty A; Greis KD; Hicks JL; Hook KE; Keller PR; Leopold WR; Loo JA; McNamara DJ; Nelson JM; Sherwood V; Smaill JB; Trumpp-Kallmeyer S; Dobrusin EM
Proc Natl Acad Sci U S A; 1998 Sep; 95(20):12022-7. PubMed ID: 9751783
[TBL] [Abstract][Full Text] [Related]
27. Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model.
Diaz R; Nguewa PA; Parrondo R; Perez-Stable C; Manrique I; Redrado M; Catena R; Collantes M; Peñuelas I; Díaz-González JA; Calvo A
BMC Cancer; 2010 May; 10():188. PubMed ID: 20459769
[TBL] [Abstract][Full Text] [Related]
28. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways.
Xia W; Mullin RJ; Keith BR; Liu LH; Ma H; Rusnak DW; Owens G; Alligood KJ; Spector NL
Oncogene; 2002 Sep; 21(41):6255-63. PubMed ID: 12214266
[TBL] [Abstract][Full Text] [Related]
29. A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors.
Zhang J; Cao J; Li J; Zhang Y; Chen Z; Peng W; Sun S; Zhao N; Wang J; Zhong D; Zhang X; Zhang J
J Hematol Oncol; 2014 Mar; 7():22. PubMed ID: 24612546
[TBL] [Abstract][Full Text] [Related]
30. BB, a new EGFR inhibitor, exhibits prominent anti-angiogenesis and antitumor activities.
Sun QM; Miao ZH; Lin LP; Gui M; Zhu CH; Xie H; Duan WH; Ding J
Cancer Biol Ther; 2009 Sep; 8(17):1640-7. PubMed ID: 19625781
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647.
Gendreau SB; Ventura R; Keast P; Laird AD; Yakes FM; Zhang W; Bentzien F; Cancilla B; Lutman J; Chu F; Jackman L; Shi Y; Yu P; Wang J; Aftab DT; Jaeger CT; Meyer SM; De Costa A; Engell K; Chen J; Martini JF; Joly AH
Clin Cancer Res; 2007 Jun; 13(12):3713-23. PubMed ID: 17575237
[TBL] [Abstract][Full Text] [Related]
32. Rationale for Using Irreversible Epidermal Growth Factor Receptor Inhibitors in Combination with Phosphatidylinositol 3-Kinase Inhibitors for Advanced Head and Neck Squamous Cell Carcinoma.
Michmerhuizen NL; Leonard E; Matovina C; Harris M; Herbst G; Kulkarni A; Zhai J; Jiang H; Carey TE; Brenner JC
Mol Pharmacol; 2019 May; 95(5):528-536. PubMed ID: 30858165
[TBL] [Abstract][Full Text] [Related]
33. Achieving selectivity between highly homologous tyrosine kinases: a novel selective erbB2 inhibitor.
Bhattacharya SK; Cox ED; Kath JC; Mathiowetz AM; Morris J; Moyer JD; Pustilnik LR; Rafidi K; Richter DT; Su C; Wessel MD
Biochem Biophys Res Commun; 2003 Jul; 307(2):267-73. PubMed ID: 12859950
[TBL] [Abstract][Full Text] [Related]
34. Novel scaffold hopping of potent benzothiazole and isatin analogues linked to 1,2,3-triazole fragment that mimic quinazoline epidermal growth factor receptor inhibitors: Synthesis, antitumor and mechanistic analyses.
Rezki N; Almehmadi MA; Ihmaid S; Shehata AM; Omar AM; Ahmed HEA; Aouad MR
Bioorg Chem; 2020 Oct; 103():104133. PubMed ID: 32745759
[TBL] [Abstract][Full Text] [Related]
35. Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells.
Xu H; Stabile LP; Gubish CT; Gooding WE; Grandis JR; Siegfried JM
Clin Cancer Res; 2011 Jul; 17(13):4425-38. PubMed ID: 21622718
[TBL] [Abstract][Full Text] [Related]
36. Combined treatment with silibinin and epidermal growth factor receptor tyrosine kinase inhibitors overcomes drug resistance caused by T790M mutation.
Rho JK; Choi YJ; Jeon BS; Choi SJ; Cheon GJ; Woo SK; Kim HR; Kim CH; Choi CM; Lee JC
Mol Cancer Ther; 2010 Dec; 9(12):3233-43. PubMed ID: 21159609
[TBL] [Abstract][Full Text] [Related]
37. Bay846, a new irreversible small molecule inhibitor of EGFR and Her2, is highly effective against malignant brain tumor models.
Longo SL; Padalino DJ; McGillis S; Petersen K; Schirok H; Politz O; Canute GW; Post DE
Invest New Drugs; 2012 Dec; 30(6):2161-72. PubMed ID: 22203214
[TBL] [Abstract][Full Text] [Related]
38. Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.
Leto SM; Sassi F; Catalano I; Torri V; Migliardi G; Zanella ER; Throsby M; Bertotti A; Trusolino L
Clin Cancer Res; 2015 Dec; 21(24):5519-31. PubMed ID: 26296355
[TBL] [Abstract][Full Text] [Related]
39. Click chemistry for improvement in selectivity of quinazoline-based kinase inhibitors for mutant epidermal growth factor receptors.
Song J; Jang S; Lee JW; Jung D; Lee S; Min KH
Bioorg Med Chem Lett; 2019 Feb; 29(3):477-480. PubMed ID: 30554954
[TBL] [Abstract][Full Text] [Related]
40. ERBB1 and ERBB2 have distinct functions in tumor cell invasion and intravasation.
Kedrin D; Wyckoff J; Boimel PJ; Coniglio SJ; Hynes NE; Arteaga CL; Segall JE
Clin Cancer Res; 2009 Jun; 15(11):3733-9. PubMed ID: 19458057
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]